Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT04079738

Recruitment Status : Terminated (Funder requested termination due to halting internal development of TAK-659)

First Posted : September 6, 2019

Last Update Posted : March 31, 2022

View this study on Beta.ClinicalTrials.gov

Sponsor:

Collaborator:

Takeda

Information provided by (Responsible Party):

H Scott Boswell, Big Ten Cancer Research Consortium

Results Submitted - Quality Control (QC) Review Has Not Concluded

Results information for an applicable clinical trial (ACT) is posted within 30 days of submission even if the submission has not completed the ClinicalTrials.gov Results Quality Control (QC) review process. Results information is submitted to ClinicalTrials.gov by the sponsor or investigator, and National Library of Medicine (NLM) staff assess for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.

All versions of ACT results information submissions that have not completed the QC review process are posted on ClinicalTrials.gov (since January 2020). After the QC review process is completed, the results information is posted without QC review comments and previous versions are archived.

Recruitment Status :	Terminated
Actual Primary Completion Date :	September 22, 2021
Actual Study Completion Date :	February 23, 2022

Submission Cycle	Results Submitted to ClinicalTrials.gov	Results Returned after Quality Control Review
1	April 11, 2022	May 5, 2022 Submission with QC Comments
2	August 26, 2022	September 20, 2022 Submission with QC Comments
3	March 11, 2023	April 5, 2023 Submission with QC Comments

To Top